Studies have shown that activation of the YAP/TAZ pathway in hepatocellular carcinoma (H.C.C.)can suppress the immune response to cancer, reducing the efficacy of immunotherapy [172]. This evidence concerns the gene YAP1 and hepatocellular carcinoma.